Adicet Bio reported a net loss of $26.9 million for Q3 2025, an improvement from $30.5 million in Q3 2024. The company's R&D and G&A expenses both decreased, contributing to the reduced loss. Adicet also announced positive preliminary safety and efficacy data from its Phase 1 clinical trial of ADI-001 in lupus nephritis and systemic lupus erythematosus, and successfully raised $74.8 million in net proceeds from a registered direct offering, extending its cash runway into the second half of 2027.
Net loss for Q3 2025 was $26.9 million, an improvement from $30.5 million in the same period last year.
Research and Development expenses decreased to $22.9 million in Q3 2025 from $26.3 million in Q3 2024.
General and Administrative expenses decreased to $5.1 million in Q3 2025 from $6.9 million in Q3 2024.
The company successfully raised $74.8 million in net proceeds from a registered direct offering in October 2025, extending its cash runway into the second half of 2027.
Adicet Bio plans to request a meeting with the FDA in Q1 2026 to discuss the pivotal trial design for ADI-001, with initiation anticipated in Q2 2026. The company also expects to submit a regulatory filing for ADI-212 in mCRPC in Q1 2026 and share initial clinical data in H2 2026. The recent capital raise has extended the cash runway into H2 2027.
Analyze how earnings announcements historically affect stock price performance